Journal of Scientific and Industrial Research

Open Access Open Access  Restricted Access Subscription Access

Identification of Herbal Molecules for the Treatment of Alzheimer's Disease Through a Combination of Molecular Docking and In-Vitro Analysis


Affiliations
1 Department of Pharmacy, Shri Jagdishprasad Jhabarmal Tibrewala University, Jhunjhunu 333 001, Rajasthan, India., India
2 Department of Pharmacology, Government College of Pharmacy, Rohru 171 207, Himachal Pradesh, India., India
 

Currently, there is a lack of therapeutic interventions that can modify the development and progression of Alzheimer's Disease (AD). The thorough pathology of AD remains unclear, creating ample opportunities for research aimed at developing innovative therapeutic approaches for managing the disease. The present research involved a literature survey to identify 100 herbal molecules that could potentially be beneficial in inhibiting Acetylcholinesterase (AChE), Butyrylcholinesterase (BChE), β-Secretase, and mitigating oxidative and inflammatory stress, as well as neurodegeneration. The herbal molecules were screened against AChE, BChE, and β-Secretase using AutoDock Tools-1.5.6 docking software with Protein Data Bank (PDB) ID 1B41, 1P0I, and 1FKN, respectively. After assessing the docking parameters, it was determined that quercetin, rutin, vitisinol-C, dihydrotanshinone-I, and β-carotene exhibited the strongest potential against their respective protein receptors. Additionally, our in-vitroAChE and BChE assay results showed that quercetin and rutin have the ability to modulate cholinergic pathways associated with AD, thusproviding potential therapeutic benefits. Our in-vitro studies on neurodegeneration revealed that quercetin and rutin exhibit a neuroprotective effect against neurodegeneration induced by HgCl2 , which suggests that they may have a potential role in protecting against neurodegeneration in AD. Nonetheless, additional preclinical investigations are essential to validate the potential effects of these molecules on AD pathogenesis.

Keywords

Acetylcholinesterase, Alzheimer’s Disease, Butyrylcholinesterase, Quercetin, Rutin.
User
Notifications
Font Size

  • Miltiadous A, Tzimourta K D, Giannakeas N, Tsipouras M G, Afrantou T, Ioannidis P & Tzallas A T, Alzheimer’s disease and frontotemporal dementia: a robust classification method of EEG signals and a comparison of validation methods, Diagnostics, 11(8)(2021) 1437, DOI: 10.3390/diagnos-tics11081437.

  • Nagu P, Parashar A, Behl T & Mehta V, CNS implications of COVID-19: A comprehensive review, Rev Neurosci,32(2) (2021) 219–234, DOI: 10.1515/revneuro-2020-0070.

  • World Health Organization, (https://www.who.int/ news-room/fact-sheets/detail/dementia), 2021.

  • Matuskova V, Ismail Z, Nikolai T, Markova H, Cechova K, Nedelska Z, Laczo J,Wang M, Hort J & Vyhnalek M, Mild behavioral impairment is associated with atrophy of entorhinal cortex and hippocampus in a memory clinic cohort, Front Aging Neurosci, 13(2021) 643271, DOI: 10.3389/fnagi.2021.643271.

  • Mushtaq G, Greig N H, Khan J A & Kamal M A, Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus, CNS Neurol Disord Drug Targets, 13(8)(2014) 1432–1439, DOI: 10.2174/1871527313666141023141545.

  • Knop F K, O’Harte F P, Seino Y & Flatt P, GLP-1 and underlying beneficial actions in Alzheimer’s disease, hypertension, and NASH, Front Endocrinol, 12(2021) 721198, DOI:10.3389/fendo.2021.721198.

  • Athar T, Al Balushi K & Khan S A, Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease, Mol Biol Rep, 48(7) (2021) 5629–5645, DOI:10.1007/s11033-021-06512-9.

  • Khazdair M R, Anaeigoudari A, Hashemzehi M & Mohebbati R, Neuroprotective potency of some spice herbs, a literature review, J Tradit Complement Med, 9(2)(2019) 98–105, DOI: 10.1016/j.jtcme.2018.01.002.

  • Zhao Y, Wu Y & Wang M, Bioactive substances of plant origin 30, Handbook of Food Chemistry, 967 (2015) 967–1008, DOI: 10.1007/978-3-642-36605-5_13.

  • Robbins D & Zhao Y, Manganesesuperoxide dismutase in cancer prevention, Antioxid Redox Signal, 20(10) (2014) 1628–1645, DOI: 10.1089/ars.2013.5297.

  • Menghani Y R, Bhattad D M, Chandak K K, Taksande J B & Umekar M J, A review: Pharmacological and herbal remedies in the management ofneurodegenerative disorder (Alzheimer’s), Int J Pharmacogn Life Sci, 2(1)(2021) 18–27, DOI: 10.33545/27072827.2021.v2.i1a.23.

  • Ivanova L, Karelson M & Dobchev D A, Multitarget approach to drug candidates against Alzheimer’s disease related to AChE, SERT, BACE1 and GSK3βprotein targets, Molecules, 25(8)(2020) 1846, DOI: 10.3390/molecules 25081846.

  • Aldewachi H, Al-Zidan R N,Conner M T & Salman M M, High-throughput screening platforms in the discovery of novel drugs for neurodegenerative diseases, Bioengineering, 8(2)(2021) 30, DOI: 10.3390/bioengineering8020030.

  • Trott O & Olson A J, AutoDockVina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J Comput Chem, 31(2)(2010) 455–461, DOI:10.1002/jcc.21334.

  • El-Hachem N, Haibe-Kains B, Khalil A, Kobeissy F H & Nemer G, AutoDock and AutoDockTools for protein-ligand docking: Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a case study, Methods Mol Biol, 1598 (2017) 391–403, DOI:10.1007/978-1-4939-6952-4_20.

  • Kumar A, Mehta V, Raj U, Varadwaj P K, Udayabanu M, Yennamalli R M & Singh T R, Computational and in-vitro validation of natural molecules as potential acetylcholinesterase inhibitorsand neuroprotective agents, Curr Alzheimer Res, 16(2)(2019) 116–127, DOI:10.2174/ 1567205016666181212155147.

  • Jason M K, Mohney R P & Pappan K L, Long-chain acylcholines link butyrylcholinesterase to regulation of non-neuronal cholinergic signaling, J Proteome Res, 21(3)(2021) 599–611, DOI:10.1021/acs.jproteome.1c00538.

  • Xiong N, Schiller M R, Li J,Chen X & Lin Z, Severe COVID-19 in Alzheimer’s disease: APOE4’s fault again?, Alzheimers Res Ther, 13 (1)(2021) 111, DOI:10.1186/ s13195-021-00858-9.

  • Currinn H & Wassmer T, The amyloid precursor protein (APP) binds the PIKfyve complex and modulates its function, Biochem Soc Trans, 44 (1)(2016) 185–190, DOI:10.1042/BST20150179.

  • Gupta A & Goyal R, Amyloid beta plaque: A culprit for neurodegeneration, Acta Neurol Belg, 116(4)(2016) 445–450, DOI:10.1007/s13760-016-0639-9.

  • Pu F, Mishima K, Irie K, Motohashi K, Tanaka Y, Orito K, Egawa T, Kitamura Y, Egashira N, Iwasaki K & Fujiwara M, Neuroprotective effects of quercetin and rutin on spatial memory impairment in an 8-arm radial maze task and neuronal death induced by repeated cerebral ischemia in rats, J Pharmacol Sci, 104(4) (2007) 329–334, DOI:10.1254/jphs.FP0070247.

  • Wang R, Sun Y, Huang H, Wang L, Chen J & Shen W, Rutin, a natural flavonoid protects PC12 cells against sodium nitroprusside-induced neurotoxicity through activating PI3K/Akt/mTOR and ERK1/2 pathway, Neurochem Res, 40(9)(2015) 1945–1953, DOI:10.1007/s11064-015-1690-2.

  • Moreta M P-G, Burgos-Alonso N, Torrecilla M, Marco-Contelles J & Bruzos-Cidón C, Efficacy of acetylcholinesterase inhibitors on cognitive function in Alzheimer’s disease. Review of Reviews,Biomedicines, 9(11) (2021) 1689, DOI:10.3390/biomedicines9111689.

  • Reddy M V, Rao K Y, Anusha G, Kumar G M, Damu A G, Reddy K R, Shetti N P, Aminabhavi T M & Reddy P V, In-vitroevaluation of antioxidant and anticholinesterase activities of novel pyridine, quinoxaline and s-triazine derivatives, Environ Res, 199(2021) 111320, DOI:10.1016/ j.envres.2021.111320.

  • Ongnok B, Khuanjing T, Chunchai T, Kerdphoo S, Jaiwongkam T, Chattipakorn N & Chattipakorn S C, Donepezil provides neuroprotective effects against brain injury and Alzheimer's pathology under conditions of cardiac ischemia/reperfusion injury, Biochim Biophys Acta Mol Basis Dis, 1867(1)(2021) 165975, DOI:10.1016/j.bbadis. 2020.165975.

  • Khan M T, Orhan I, Şenol F S, Kartal M U, Şener B, Dvorska M, Smejkal K & Slapetova T, Cholinesterase inhibitory activities of some flavonoid derivatives and chosen xanthone and their molecular docking studies, Chem Biol Interact, 181(3)(2009) 383–389, DOI:10.1016/ j.cbi.2009.06.024.

  • Nazir N, Nisar M, Zahoor M, Uddin F, Ullah S, Ullah R, Ansari S A, Mahmood H M,Bari A & Alobaid A. Phytochemical analysis, in vitro anticholinesterase, antioxidant activity and in vivonootropic effect of Ferula ammoniacum(Doremaammoniacum) D. Don. in scopolamine-induced memory impairment in mice, Brain Sci, 11(2)(2021) 259, DOI:10.3390/brainsci11020259.

  • Sharifi-Rad M, Lankatillake C, Dias D A, Docea A O, Mahomoodally M F, Lobine D, Chazot P L, Kurt B, Tumer T B, Moreira A C, Sharopov F, Martorell M, Martins N, Cho W C, Calina D, Sharifi-Rad J,Impact of natural compounds on neurodegenerative disorders: from preclinical to pharmacotherapeutics, J Clin Med, 9(4)(2020) 1061, DOI:10.3390/jcm9041061.

  • Zhang X D, Liu X Q, Kim Y H & Whang W K, Chemical constituents and their acetyl cholinesterase inhibitory and antioxidant activities from leaves of Acanthopanax henryi: potential complementary source against Alzheimer’s disease, Arch Pharm Res, 37(5) (2014) 606–616, DOI:10.1007/ s12272-013-0252-x.

  • Khan H, Ullah H, Aschner M, Cheang W S & Akkol E K, Neuroprotective effects of quercetin in Alzheimer’s disease, Biomolecules, 10(1)(2020) 59, (DOI:10.3390/ biom10010059).

  • Shanmugasundaram D & Roza J M, Assessment of anti-inflammatory and antioxidant activity of quercetin–rutin blend (SophorOx™)–an in vitrocell based assay,J Complement Integr Med, 19(3) (2022) 637–644, DOI:10.1515/jcim-2021-0568.

  • Jiang X, Zhang Z, Zuo J, Wu C,Zha L, Xu Y, Wang S, Shi J, Liu X H, Zhang J & Tang W, Novel cannabidiol- carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease, Eur J Med Chem, 5(223) (2021) 113735, DOI:10.1016/j.ejmech. 2021.113735.

  • Barbosa M F, Justino A B, Martins M M, Belaz K R, Ferreira F B, de Oliveira R J, Danuello A, Espindola F S & Pivatto M, Cholinesterase inhibitors assessment of aporphine alkaloids from Annona crassifloraand molecular docking studies, Bioorg Chem, (2022) 105593, DOI:10.1016/j.bioorg.2021.105593.

  • Nordberg A, Ballard C, Bullock R, Darreh-Shori T &Somogyi M, A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease, Prim Care Companion CNS Disord, 15(2) (2013) 26731, DOI: 10.4088/PCC.12r01412.

  • Abbou F, Azzi R, Ouffai K, El Haci I A, Belyagoubi-Benhammou N, Bensouici C &Benamar H, Phenolic profile, antioxidant and enzyme inhibitory properties of phenolic-rich fractions from the aerial parts of MenthapulegiumL, S Afr J Bot, 146(2022) 196–204, DOI:10.1016/j.sajb.2021.10.024.

  • Tundis R, Cappello A R, Bonesi M, Peruzzi L &Loizzo M R, Extracts of different polarity of Daphne laureolaL. as valuable source of antioxidant and neuroprotective compounds, Med Sci Forum, 2(1)(2021) 19, DOI:10.3390/CAHD2020-08560).

  • Yang M, Xuan Z, Wang Q, Yan S, Zhou D, Naman C B, Zhang J, He S, Yan X & Cui W, Fucoxanthin has potential for therapeutic efficacy in neurodegenerative disorders by acting on multiple targets, Nutr Neurosci, 14(2022) 1–4, DOI:10. 1080/1028415X.2021.1926140.

  • Bhat I U & Bhat R, Quercetin: A bioactive compound imparting cardiovascular and neuroprotective benefits: scope for exploring fresh produce, their wastes, and by-products, Biology, 10(7) (2021) 586, DOI:10.3390/biology10070586.


Abstract Views: 50

PDF Views: 44




  • Identification of Herbal Molecules for the Treatment of Alzheimer's Disease Through a Combination of Molecular Docking and In-Vitro Analysis

Abstract Views: 50  |  PDF Views: 44

Authors

Priyanka Nagu
Department of Pharmacy, Shri Jagdishprasad Jhabarmal Tibrewala University, Jhunjhunu 333 001, Rajasthan, India., India
Amjad Khan A Pathan
Department of Pharmacy, Shri Jagdishprasad Jhabarmal Tibrewala University, Jhunjhunu 333 001, Rajasthan, India., India
Vineet Mehta
Department of Pharmacology, Government College of Pharmacy, Rohru 171 207, Himachal Pradesh, India., India

Abstract


Currently, there is a lack of therapeutic interventions that can modify the development and progression of Alzheimer's Disease (AD). The thorough pathology of AD remains unclear, creating ample opportunities for research aimed at developing innovative therapeutic approaches for managing the disease. The present research involved a literature survey to identify 100 herbal molecules that could potentially be beneficial in inhibiting Acetylcholinesterase (AChE), Butyrylcholinesterase (BChE), β-Secretase, and mitigating oxidative and inflammatory stress, as well as neurodegeneration. The herbal molecules were screened against AChE, BChE, and β-Secretase using AutoDock Tools-1.5.6 docking software with Protein Data Bank (PDB) ID 1B41, 1P0I, and 1FKN, respectively. After assessing the docking parameters, it was determined that quercetin, rutin, vitisinol-C, dihydrotanshinone-I, and β-carotene exhibited the strongest potential against their respective protein receptors. Additionally, our in-vitroAChE and BChE assay results showed that quercetin and rutin have the ability to modulate cholinergic pathways associated with AD, thusproviding potential therapeutic benefits. Our in-vitro studies on neurodegeneration revealed that quercetin and rutin exhibit a neuroprotective effect against neurodegeneration induced by HgCl2 , which suggests that they may have a potential role in protecting against neurodegeneration in AD. Nonetheless, additional preclinical investigations are essential to validate the potential effects of these molecules on AD pathogenesis.

Keywords


Acetylcholinesterase, Alzheimer’s Disease, Butyrylcholinesterase, Quercetin, Rutin.

References